Company Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.
The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors.
In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus.
The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer’s disease, and depression.
It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Dec 3, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 280 |
| CEO | Bassil Dahiyat |
Contact Details
Address: 465 North Halstead Street, Suite 200 Pasadena, California 91107 United States | |
| Phone | 626 305 5900 |
| Website | xencor.com |
Stock Details
| Ticker Symbol | XNCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326732 |
| CUSIP Number | 98401F105 |
| ISIN Number | US98401F1057 |
| Employer ID | 20-1622502 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. John R. Desjarlais Ph.D. | Executive Vice President of Research and Chief Scientific Officer |
| Celia E. Eckert J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Nancy Valente M.D. | Executive Vice President and Chief Development Officer |
| Bart Jan Cornelissen | Senior Vice President and Chief Financial Officer |
| Charles Liles | Associate Director and Head of Corporate Communications and Investor Relations |
| Jennifer Sandoz | Senior VIce President of Human Resources |
| Dr. Jeremy Grunstein Ph.D. | Senior Vice President of Business Development |
| Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Eric P. Kowack | Senior Vice President of Program Leadership and Alliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 12, 2024 | 8-K | Current Report |